Bronchiectasis in immunodeficiency

PURPOSE OF REVIEW: As the field of bronchiectasis continues to advance, so does the recognition of undiagnosed immunodeficiency as a potential contributor. This review aims to highlight what is currently known about bronchiectasis in immunodeficiency as well as explore future therapeutics and needs. RECENT FINDINGS: Guidelines emphasize the need for evaluation for underlying immunodeficiency in patients with known bronchiectasis. Despite this known association, evaluation continues to be variable in clinical practice resulting in potentially missed therapeutic options, such as immunoglobulin replacement therapy in the setting of immunodeficiency. While the mainstay treatment for those with bronchiectasis and immunodeficiency continues to be immunoglobulin replacement therapy and prophylactic antibiotics, the future is hopeful with more directed therapy for the underlying pathophysiology of bronchiectasis with targeted agents such as brensocatib. SUMMARY: This review highlights the need for ongoing research to improve detection of bronchiectasis in immunodeficiency and include patients with immunodeficiency and bronchiectasis in trial designs for therapeutics in bronchiectasis.